Description
1) Esketamine (Janssen Pharmaceutical Ltd., USA) Ella J. Daly (edaly2@its.jnj.com) or Jaskaran B. Singh (jsingh25@its.jnj.com) 2) (R)-Ketamine: Kenji Hashimoto (Chiba University, Japan) e-mail: hashimoto@faculty.chiba-u.jp 3) (2R,6R)-HNK (metabolite of R-ketamine): Todd D. Gould (University of Maryland, USA) (gouldlab@me.com) or Panos Zanos (panoszanos1986@gmail.com) 4) Lanicemine and BHV-5000 (low-trapping NMDAR antagonist) Biohaven Pharmaceutical (http://biohavenpharma.com/) 5) Rapastinel and Apimostinel: (Naurex OR Allergan) Joseph R. Moskal (Northwestern University, USA)( j-moskal@northwestern.edu) 6) AV-101 (L-4-chlorokynurenine: NMDAR glycine site antagonist): VistaGen Therapeutics (https://www.vistagen.com/) 7) TAK-653 (AMPAR potentiator): Haruhide Kimura (Takeda Pharmaceutical Co., Ltd, Japan) e-mail: haruhide.kimura@takeda.com 8) mGluR2/3 antagonists: Shigeyuki Chaki (Taisho Pharmaceutical Co, Ltd, Japan) e-mail: s-chaki@taisho.co.jp 9) SAGE-217 PAM at GABA-A: Sage Therapeutics, Inc. USA (https://www.sagerx.com/) 10) NAM at alpha-5 GABA-A: Scott M. Thompson (University of Maryland, USA) e-mail: sthompson@som.umaryland.edu 11) Scopolamine (muscarinic AChR antagonist): Ronald S. Duman (Yale University, USA) e-mail: ronald.duman@yale.edu 12) Sirukumab (IL-6 antibody)(Janssen Pharmaceutical Co, Ltd) Roger S. McIntyre (University of Toronto: roger.mcintyre@uhn.ca) 13) Seltorexant (orexin-2 receptor antagonist): Janssen Pharmaceutical Ltd. (Peter De Boer: pdeboer1@jts.jmj.com) OR Minera Neuroscience Inc. (Remy Luthringer) (http://www.minervaneurosciences.com/) 14) JNJ-55308942 (P2X7 antagonist) Anindya Bhattacharya (J&J, abhatta2@its.jnj.com) 15) Psilocybin (psychedelic drug) Compass Pathway (https://compasspathways.com/)
